TOP > 外国特許検索 > Human abzyme

Human abzyme

外国特許コード F170009200
整理番号 AF12-05EP4
掲載日 2017年9月12日
出願国 欧州特許庁(EPO)
出願番号 15155990
公報番号 2894222
公報番号 2894222
出願日 平成23年2月21日(2011.2.21)
公報発行日 平成27年7月15日(2015.7.15)
公報発行日 平成30年8月22日(2018.8.22)
国際出願番号 JP2011053752
国際公開番号 WO2011102517
国際出願日 平成23年2月21日(2011.2.21)
国際公開日 平成23年8月25日(2011.8.25)
優先権データ
  • 特願2010-034998 (2010.2.19) JP
  • 特願2010-035021 (2010.2.19) JP
  • 特願2010-092461 (2010.4.13) JP
  • 20110744803 (2011.2.21) EP
  • 2011JP53752 (2011.2.21) WO
発明の名称 (英語) Human abzyme
発明の概要(英語) The present invention provides a human abzyme containing a human antibody º light chain.
従来技術、競合技術の概要(英語) Background Art
The inventers of the present invention have conducted various and ingenious researches into abzymes (for example, refer to Patent Literature 1). Conventionally, abzymes which include fully human sequence have been obtained only from Bence Jones protein (BJP) that is obtained from multiple myeloma patients. The number of multiple myeloma patients is small, and besides, only a few BJP contain enzyme activity, so that it has been difficult to obtain human abzymes. However, side effects of human abzymes for a human body are expected to be less. Therefore, domestic and international pharmaceutical companies etc. have longed for useful human abzymes to be developed.
By the way, rabies is an infectious disease which still imposes a heavy disease burden in developing countries and a fatal disease with 100% of mortality rate at a time of the onset of rabies. There is no effective treatment for rabies at this time other than administration of vaccine to prevent rabies from developing after exposure to rabies viruses. Therefore, development of a treatment for rabies from a new viewpoint is desired.
The international patent application published under the reference WO2004/106375 discloses human rabies-neutralizing antibodies.
Also, influenza viruses are so diverse in their antigenicity that influenza spreads wide and causes serious damage. Therefore, development of a treatment for influenza from a new viewpoint is desired.
Citation List
Patent Literatures
Patent Literature 1
Japanese Patent Application Publication, Tokukai No. 2006-197930 (Publication Date: August 3, 2006)
Patent Literature 2
Japanese Patent Application Publication, Tokukai No. 2004-97211 (Publication Date: April 2, 2004)

特許請求の範囲(英語) [claim1]
1. A human abzyme being a human antibody κ light chain against rabies virus and having a variable domain consisting of a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 50.

[claim2]
2. The human abzyme as set forth in Claim 1, wherein the human abzyme has an anti-influenza virus activity and nucleolytic activity.

[claim3]
3. An antiviral agent for use in the prevention of and/or treatment of an influenza virus infectious disease comprising a human abzyme recited in claim 1 or 2.
  • 出願人(英語)
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • Uda, Taizo
  • Hifumi, Emi
  • Nioshizono, Akira
  • Arakawa, Mitsue
国際特許分類(IPC)
指定国 Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
参考情報 (研究プロジェクト等) CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close